Holen Sie sich die Stockscreener-App
6.3609
2.58%
0.1609
Schlusskurs vom Vortag:
$6.20
Offen:
$6.23
24-Stunden-Volumen:
1.02M
Relative Volume:
0.66
Marktkapitalisierung:
$1.30B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-129.48M
KGV:
-11.39
EPS:
-0.5584
Netto-Cashflow:
$-106.97M
1W Leistung:
+3.25%
1M Leistung:
+24.95%
6M Leistung:
+10.22%
1J Leistung:
+171.79%
1-Tages-Spanne:
$6.17
$6.475
1-Wochen-Bereich:
$6.00
$6.475
52-Wochen-Spanne:
$2.23
$7.005
Savara Inc Stock (SVRA) Company Profile
Firmenname
Savara Inc
Sektor
Branche
Telefon
51285113796
Adresse
6836 BEE CAVE ROAD, AUSTIN, TX
Compare SVRA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
6.36 | 1.27B | 0 | -129.48M | -106.97M | -0.5584 |
VRTX
Vertex Pharmaceuticals Inc
|
524.75 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.67 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
920.36 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
319.89 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
191.85 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-24 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-08-15 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-05-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-12-20 | Eingeleitet | Wells Fargo | Overweight |
| 2024-11-13 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-02-15 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-11-07 | Eingeleitet | Guggenheim | Buy |
| 2023-05-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-03-31 | Herabstufung | Jefferies | Buy → Hold |
| 2021-03-16 | Eingeleitet | Piper Sandler | Overweight |
| 2021-03-15 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-13 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-13 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-13 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2018-08-13 | Fortgesetzt | ROTH Capital | Neutral |
| 2018-01-03 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-09-27 | Fortgesetzt | ROTH Capital | Buy |
| 2017-09-22 | Eingeleitet | Jefferies | Buy |
| 2017-09-11 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Savara Inc Aktie (SVRA) Neueste Nachrichten
Enterprise value to EBIT forward of Savara, Inc. – NASDAQ:SVRA - TradingView
Savara Inc focuses on respiratory drug development as investors watch clinical progress - AD HOC NEWS
Price to sales forward of Savara, Inc. – NASDAQ:SVRA - TradingView
Enterprise value to revenue forward of Savara, Inc. – NASDAQ:SVRA - TradingView
Savara Inc. (SVRA) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of November 7, 2025 Deadline - The National Law Review
SVRA Q1 2026 Earnings: EPS Misses Estimates as Clinical Development AdvancesGrowth Acceleration Report - dars.gov.et
Securities Lawsuit Alert: Savara Inc. (SVRA) InvestorsContact Levi & Korsinsky Before November 7, 2025 - The National Law Review
Class Action Lawsuit Alert: Levi & Korsinsky Reminds Savara Inc. (SVRA) Investors of November 7, 2025 Deadline - The National Law Review
SVRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Levi & Korsinsky Notifies Savara Inc. (SVRA) InvestorsLead Plaintiff Deadline on November 7, 2025 - The National Law Review
Investors SueWallSt as Savara Inc. Faces Securities Fraud Allegations - The National Law Review
Investors in Savara Inc. (SVRA): Protect Your RightsContact Levi & Korsinsky Before November 7, 2025 - The National Law Review
Savara, Inc. Actuals & Estimates (FWB:YB4P) - TradingView
SVRA Forecast — Price Target — Prediction for 2027 - TradingView
What Does the FDA's Priority Review Mean for Savara's MOLBREEVI - Kavout | AI
Savara, Inc. Actuals & Estimates (SWB:YB4P) - TradingView
YB4P Forecast — Price Target — Prediction for 2027 - TradingView
Savara Inc (SVRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Savara CFO David Lowrance sells $2.24m in company stock By Investing.com - Investing.com Australia
Savara CFO David Lowrance sells $2.24m in company stock - Investing.com UK
Form 4 Savara Inc For: 22 June By Investing.com - Investing.com Nigeria
Savara (SVRA) CFO exercises 580K options and sells 394K shares in Form 4 - Stock Titan
Form 144 Savara Inc For: 22 June By Investing.com - Investing.com South Africa
[144] Savara Inc SEC Filing - Stock Titan
Does Savara’s Expanded Share Pool and CFO Shift Reframe Its Capital Strategy Narrative (SVRA)? - simplywall.st
Savara StockLong-term pipeline story in rare lung disease - AD HOC NEWS
Savara Grants Equity Awards to New Hires Amid Growth Push - MyChesCo
Savara Inc (SVRA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Savara Inc (SVRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Savara Shifts Finance Leadership Ahead of Key Drug Milestone - MyChesCo
Savara Inc (SVRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Savara Inc (SVRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Savara Inc (SVRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Savara Inc (SVRA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Savara Inc (SVRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Savara Inc (SVRA) Institutional Confidence - TradingKey
Savara (SVRA) Proxy filing Summary - Quartr
H.C. Wainwright Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $10 - Moomoo
What Is Driving Attention Toward Savara’s Rare Disease Strategy? - Kalkine Media
Savara: Lowrance Will Remain Available in Advisory Capacity >SVRA - Moomoo
Savara Announces New Employment Inducement Grant - Business Wire
How Investors Are Reacting To Savara (SVRA) Doubling Share Authorization And Reshaping Its CFO Role - simplywall.st
SVRA Q1 2026 Earnings: EPS Misses Estimates as Pre‑Revenue Biotech Continues R&D Spend - dars.gov.et
LifeSci Capital Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Savara shareholders approve share increases and executive changes at annual meeting - Investing.com Australia
Savara (SVRA) Announces Leadership Changes in Finance Department - GuruFocus
Finanzdaten der Savara Inc-Aktie (SVRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Savara Inc-Aktie (SVRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lowrance David L | Chief Financial Officer |
Jun 22 '26 |
Sale |
5.68 |
394,528 |
2,241,432 |
536,032 |
1.67%
3.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):